Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasculitis associated with connective tissue disorders.

Mittie K Doyle1

  • 1Centocor Research & Development, 200 Great Valley Parkway, Malvern, PA 19355, USA. mdoyle1@cntus.jnj.com

Current Rheumatology Reports
|July 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet (London, England)·2022
Same author

Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

The journal of pain·2019
Same author

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Annals of the rheumatic diseases·2014
Same author

The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

The American journal of the medical sciences·2013
Same author

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.

Annals of the rheumatic diseases·2013
Same author

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Arthritis care & research·2013
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same journal

Management of IgG4-Related Disease.

Current rheumatology reports·2026
See all related articles

Vasculitis linked to connective tissue disorders is a serious condition that worsens prognosis. Early diagnosis and treatment of this secondary vasculitis are crucial for better patient outcomes.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Vasculitis associated with connective tissue disorders (CTD) is a significant cause of secondary vasculitis.
  • It often correlates with increased disease severity and poorer prognosis in patients with underlying CTDs.

Purpose of the Study:

  • To review recent insights into the clinical presentation of vasculitis in CTD.
  • To explore potential pathogenic mechanisms involved in CTD-associated vasculitis.

Main Methods:

  • Literature review focusing on recent studies.
  • Analysis of clinical presentations and pathogenic mechanisms.

Main Results:

  • Vasculitis in CTD can affect multiple organ systems with diverse presentations.

Related Experiment Videos

  • Disease severity and prognosis are often negatively impacted by vasculitis in CTD.

    • Conclusions:

    • Prompt recognition and treatment of vasculitis are vital for improving patient outcomes.
    • Understanding the clinical features and pathogenesis is key for managing this condition.